Josep Castellví Vives Institutions of which they are part Translational Molecular Pathology Vall Hebron Institut de Recerca Email Josep Castellví Vives Email Institutions of which they are part Translational Molecular Pathology Vall Hebron Institut de Recerca
Research lines Study of CAP-dependent and CAP-independent signalling pathways in breast carcinomas. In previous works we studied several factors involved in cell signalling pathways that control cell growth. The found that the phosphorylated form of 4E-BP1 was the only factor that correlated with prognosis, and histologic aggressive features in several types of cancers. 4E-BP1 is a key regulator of CAP-dependent traslation and its main function is the inactivation of eIF4E. However, not all the aggressive tumors show activation of this factor. On the other hand, it has been shown that under hypoxia conditions cells the translation of some key factors can be regulated by CAP-independent pathways, mediated by factors known as ITAFs. The aim of our study is to find the CAP-depdendent/CAP-independent balance in tumors in relation to hypoxia, and evaluate its impact on prognosis. IP: Josep Castellví Vives Projects inhibición de la comunicación celular para la prevención del desarrollo de metástasis y la resistencia a terapias antitumorales. Desarrollo de dos nuevas aproximaciones terapéuticas IP: Santiago Ramon y Cajal Agüeras Collaborators: Maria Rosa Somoza Lopez de Haro, Josep Castellví Vives, Sara Garcia Ortega, Elena Muro Blanc, Marta Cano Galietero, Javier Hernandez Losa, Marta Sese Faustino, Stefan Hummer, Lourdes Elena Salazar Huayna Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI23/01754 Duration: 01/01/2024 - 31/12/2026 INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization – INGENIO IP: Santiago Ramon y Cajal Agüeras Collaborators: Jordi Temprana Salvador, Josep Castellví Vives, Joaquim Mateo Valderrama, Javier Hernandez Losa, Vicente Peg Camara, Irene Sansano Valero Funding agency: Instituto de Salud Carlos III Funding: 80400 Reference: PMP21/00107 Duration: 01/01/2022 - 31/12/2025 Patologia molecular translacional IP: Santiago Ramon y Cajal Agüeras Collaborators: Cleofé Romagosa Pérez-Portabell, Maria Rosa Somoza Lopez de Haro, Jordi Temprana Salvador, Teresa Moline Marimon, Jessica Camacho Soriano, Carmela Iglesias i Felip, Josep Castellví Vives, Elena Muro Blanc, Marta Cano Galietero, Elena Antima Martinez Saez, Javier Hernandez Losa, Marta Sese Faustino, Vicente Peg Camara, Irene Sansano Valero, Trond Aasen, Stefan Hummer Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 01138 Duration: 01/01/2022 - 30/06/2025 Enhancing CD8+ Resident Memory T cell function to control and eliminate viral reservoirs IP: Meritxell Genesca Ferrer Collaborators: Vicente Descalzo Jorro, Josep Castellví Vives, Laura Mañalich Barrachina Funding agency: Instituto de Salud Carlos III Funding: 171820 Reference: PI20/00160 Duration: 01/01/2021 - 30/06/2025 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 … Next page › Last page »
